SABER Steering Committee Member Dr. Paula Brown Highlights Urgent Need for Scientific Clarity on Kratom at International Symposium
Dr. Brown, a recognized expert in natural health and food product research, addressed the complexities surrounding kratom, a botanical used traditionally in Southeast Asia and increasingly in the United States for pain relief, and increased focus to SunnySide Supplement Journal. She highlighted the confusion and misinformation in the marketplace, particularly concerning synthetic derivatives like 7-hydroxymitragynine (7-OH). Dr. Brown asserted, 'Synthetic 7-OH is not kratom—it is a highly potent, unregulated chemical,' underscoring the potential public health risks associated with such products. (Read the articlehere.)
The symposium, held in February, brought together leading researchers from institutions such as the University of Florida, Johns Hopkins University, and Universiti Sains Malaysia. Discussions focused on advancing scientific understanding of kratom's safety and efficacy, as well as addressing regulatory challenges. Dr. Brown emphasized the importance of distinguishing between traditional kratom products and synthetic isolates to ensure consumer safety and informed decision-making.
As a member of the SABER Steering Committee, Dr. Brown continues to advocate for evidence-based policies and practices in the natural products industry. Her participation in the symposium reflects SABER's commitment to fostering scientific research and regulatory clarity in emerging sectors.
About Scientific Association for Botanical Education and Research (SABER)
The Scientific Association for Botanical Education and Research (SABER) is a nonprofit organization dedicated to advancing scientific understanding, regulation, and safe access to botanicals. Through research partnerships, policy advocacy, and public education, SABER works to ensure that natural products are studied responsibly, used safely, and regulated appropriately. To learn more, visit www.saberscience.org.
Media Contact
Paloma Lehfeldt
[email protected]
###
SOURCE: Scientific Association for Botanical Education and Research (SABER)
Copyright 2025 EZ Newswire
https://app.eznewswire.com/news/saber-steering-committee-member-dr-paula-brown-highlights-urgent-need-for-scientific-clarity-on-kratom-at-international-symposium
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
35 minutes ago
- Washington Post
Asking Eric: Wife left a gift to niece in her will, but I hesitate to honor it
Dear Eric: When my wife and I updated our wills, she designated a diamond tennis bracelet and diamond stud earrings to her niece (she had no biological children of her own). Later that month my wife was diagnosed with pancreatic cancer to which she would succumb 19 months later. My daughter (my wife's stepdaughter) is a radiation oncologist and became our daily advocate as we navigated the byzantine world of cancer treatment.
Forbes
an hour ago
- Forbes
Sell HIMS Stock Ahead of Its Earnings?
Hims & Hers Health (NYSE:HIMS) is set to announce its earnings on Monday, August 4, 2025. Historically, HIMS stock has reacted unfavorably to earnings announcements. Since 2021, the stock has recorded a negative one-day return in 53% of instances after results. The median one-day decline has amounted to -5.8%, with a maximum one-day decrease of -22.3%. For traders focused on events, grasping these historical trends can be beneficial. While the actual results compared to consensus and expectations will be vital, there are two main strategies to contemplate: Analysts expect HIMS to report earnings of $0.23 per share on revenues of $552 million. This would mark substantial growth compared to the same quarter last year, which recorded earnings of $0.16 per share on revenues of $315 million. A possible positive factor for Hims & Hers' sales growth momentum is the reported underperformance of Novo Nordisk's weight loss medication in the U.S. due to the presence of compounded versions. Regarding fundamentals, HIMS has a market capitalization of $15 billion. Over the past twelve months, the company generated $1.8 billion in revenue and was operationally profitable, reporting $110 million in operating profits and a net income of $164 million. However, if you're looking for upside with less volatility than individual stocks, the Trefis High Quality portfolio offers an alternative — it has outperformed the S&P 500 and achieved returns exceeding 91% since its inception. Additionally, see – Is There More Upside For MSFT Stock? Review earnings reaction history of all stocks HIMS Stock Historical Likelihood of Positive Post-Earnings Return Here are some insights on one-day (1D) post-earnings returns: Additional information regarding the observed 5-Day (5D) and 21-Day (21D) returns post earnings is summarized along with the statistics in the table below. HIMS Stock Correlation Between 1D, 5D, and 21D Historical Returns A comparatively lower-risk strategy (though not effective if the correlation is weak) is to understand the relationship between short-term and medium-term returns post earnings, identify a pair that has the highest correlation, and perform the corresponding trade. For instance, if 1D and 5D exhibit the highest correlation, a trader can take a "long" position for the next 5 days if the 1D post-earnings return is positive. Here is some correlation information based on a 5-year and 3-year (more recent) timeframe. Note that the correlation 1D_5D denotes the relationship between 1D post-earnings returns and subsequent 5D returns. Discover more about the Trefis RV strategy that has outperformed its all-cap stocks benchmark (a blend of the S&P 500, S&P mid-cap, and Russell 2000), delivering strong results for investors. Additionally, if you seek upside with a smoother experience than an individual stock like Hims & Hers Health, consider the High Quality portfolio, which has surpassed the S&P and yielded >91% returns since its inception.
Yahoo
an hour ago
- Yahoo
SpaceX fires up Starship spacecraft ahead of 10th test flight (video, photos)
When you buy through links on our articles, Future and its syndication partners may earn a commission. SpaceX just fired up its newest Starship spacecraft on Thursday (July 31), to help prep the vehicle for an upcoming test flight. The company conducted a "static fire" trial with the 171-foot-tall (52 meters) Starship upper stage at its Starbase site in South Texas on Thursday, briefly igniting one of the vehicle's six Raptor engines. "Starship single-engine static fire demonstrating an in-space burn complete on Pad 1 at Starbase," SpaceX wrote in a Thursday evening X post that shared two photos and a video of the milestone. The test is part of the prep work for Flight 10 of Starship, the huge, fully reusable rocket that SpaceX is developing to help humanity colonize Mars and do a wide variety of other spaceflight work. Starship consists of two elements — the upper-stage spacecraft, called Starship or simply Ship, and a huge booster known as Super Heavy. Both are made of stainless steel and are powered by Raptors (33 of them in Super Heavy's case). This particular Ship is the second that SpaceX has earmarked for Flight 10. The first exploded on a test stand at Starbase on June 18 just before a planned static-fire test. The Super Heavy that will fly on Flight 10 has already passed its static-fire test, igniting all 33 of its engines on June 6. Related Stories: — SpaceX's Starship explodes in Texas during preparations for 10th test flight — SpaceX reached space with Starship Flight 9 launch, then lost control of its giant spaceship (video) — Starship and Super Heavy explained SpaceX has not yet announced a target date for Flight 10, but we may not have to wait long for it: company founder and CEO Elon Musk has said the test mission will launch in August. A fully stacked Starship first flew in April 2023. The huge rocket has launched three times so far this year, in January, March and May. On all three flights, SpaceX lost the upper stage before its planned Indian Ocean splashdown.
